Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Genes & Development
|
February 9, 2026
The conserved N-terminal SANT1-binding domain (SBD) of EZH2 regulates PRC2 activity
Agata L Patriotis, Douglas W Barrows, Yadira Soto-Feliciano, et al.
Neuron
|
September 4, 2021
Chromatin-mediated alternative splicing regulates cocaine-reward behavior
Song-Jun Xu, Sonia I Lombroso, Delaney K Fischer, et al.
Nature Communications
|
October 27, 2017
Characterization of histone acylations links chromatin modifications with metabolism
Johayra Simithy, Simone Sidoli, Zuo-Fei Yuan, et al.
Blood Advances
|
July 24, 2025
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML
Pau Montesinos, Dylan M Marchione, Christian Récher, et al.
Biorxiv : the Preprint Server for Biology
|
May 25, 2026
Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors
Dong-Min Yu, Eunice Lee, Gabriel J Starrett, et al.
Blood Neoplasia
|
January 23, 2026
Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors
Alex C H Liu, Severine Cathelin, Dhanoop Manikoth Ayyathan, et al.
Blood Advances
|
April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Courtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Nature Genetics
|
January 10, 2017
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas
Simon Papillon-Cavanagh, Chao Lu, Tenzin Gayden, et al.
Nature
|
September 6, 2019
The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape
Daniel N Weinberg, Simon Papillon-Cavanagh, Haifen Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Amir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Genes & Development
|
February 9, 2026
The conserved N-terminal SANT1-binding domain (SBD) of EZH2 regulates PRC2 activity
Agata L Patriotis, Douglas W Barrows, Yadira Soto-Feliciano, et al.
Neuron
|
September 4, 2021
Chromatin-mediated alternative splicing regulates cocaine-reward behavior
Song-Jun Xu, Sonia I Lombroso, Delaney K Fischer, et al.
Nature Communications
|
October 27, 2017
Characterization of histone acylations links chromatin modifications with metabolism
Johayra Simithy, Simone Sidoli, Zuo-Fei Yuan, et al.
Blood Advances
|
July 24, 2025
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML
Pau Montesinos, Dylan M Marchione, Christian Récher, et al.
Biorxiv : the Preprint Server for Biology
|
May 25, 2026
Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors
Dong-Min Yu, Eunice Lee, Gabriel J Starrett, et al.
Blood Neoplasia
|
January 23, 2026
Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors
Alex C H Liu, Severine Cathelin, Dhanoop Manikoth Ayyathan, et al.
Blood Advances
|
April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Courtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Nature Genetics
|
January 10, 2017
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas
Simon Papillon-Cavanagh, Chao Lu, Tenzin Gayden, et al.
Nature
|
September 6, 2019
The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape
Daniel N Weinberg, Simon Papillon-Cavanagh, Haifen Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Amir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Page
of 3